›CPAP
›Consider for high flow failure with persistent distress
›Monitor for gastric distension
›Intubation and mechanical ventilation
›If apnea or exhaustion with hypercapnia
›Preoxygenation strategy to minimize desaturation
›Post intubation sedation and analgesia plan
Medications and therapies with limited routine role
›Bronchodilators
›Routine use not recommended for classic bronchiolitis
›If trial considered, predefined response criteria
›Improved work of breathing
›Improved aeration
›Improved SpO2 with reduced support
›Albuterol trial dosing
›MDI with spacer 2 to 4 puffs
›Reassess after 10 to 15 minutes
›Nebulized albuterol 2.5 mg for 10 to 15 kg
›Weight adjusted dosing per local protocol
›Stop if no objective response
›Nebulized epinephrine
›Not recommended routinely
›Consider only in select settings per local protocol
›Corticosteroids
›Not recommended routinely
›Consider alternative diagnosis
›Asthma phenotype
›Croup overlap
›Hypertonic saline
›Not for ED routine use
›Consider inpatient pathway in select institutions
›Antibiotics
›Not indicated for uncomplicated bronchiolitis
›Indications
›Confirmed bacterial pneumonia
›Acute otitis media with clear diagnosis
›Sepsis concern
›Example inpatient pneumonia regimen
›Ampicillin IV 50 mg per kg every 6 hours for uncomplicated bacterial pneumonia
›Adjust for local resistance patterns
Evidence and guideline framing
›Guideline alignment
›Supportive care as primary therapy
›Avoid routine bronchodilator use
›Avoid routine corticosteroids
›Avoid routine antibiotics
›Avoid routine chest radiography for typical cases
›Evidence levels mapping
›High certainty recommendations for avoiding routine ineffective therapies
›Conditional trials only with objective response criteria
›Escalation based on respiratory failure physiology rather than virus identification